Global Lifestyle Archives | Page 39 of 461 | Be Korea-savvy

Archive by category Global Lifestyle

‘Hong Kong Summer Viva’: Calling All Fans to Dive into Festivals, Games and Parties – Only in Hong Kong!

‘Hong Kong Summer Viva’: Calling All Fans to Dive into Festivals, Games and Parties – Only in Hong Kong!

Here comes a citywide bash that’s jam-packed with events and activities for travellers from all corners of the world HONG KONG, May 31, 2025 (Korea Bizwire) – This summer, Hong Kong invites the world to experience “Hong Kong Summer Viva”, a season-long celebration of everything we love about summer, with exclusive experiences, parties and adventures for [...]

EU Good Food Officially Launches in Korea

EU Good Food Officially Launches in Korea

European culinary excellence arrives in Korea, embracing modern lifestyles and sustainable values SEOUL, South Korea, May 30, 2025 (Korea Bizwire) — The “EU Good Food – Good Life” campaign, funded by the European Union, was officially launched in South Korea, marking the start of its public communication activities in the country. This three-year initiative (2024–2027), co-funded [...]

Falcon Luxe Expands Private Jet Charter Offering with Block Hours Access

Falcon Luxe Expands Private Jet Charter Offering with Block Hours Access

DUBAI, United Arab Emirates, May 30, 2025 (Korea Bizwire) — Falcon Luxe, the private charter division of Falcon, part of Alex Group Investment, announces the availability of block hours private jet flight access. The concept is simple: clients pre-purchase a set number of flight hours and draw from them as needed, enjoying priority access to [...]

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical study $20 million milestone payment to be received from BeOne Medicines; Zymeworks remains eligible to receive up to $144 million in additional development and commercial milestones VANCOUVER, [...]

Unlucky Charm’: Heineken® and Self-Confessed Jinx Go to Extreme Lengths to Protect the Result at 2025 UEFA Champions League Final

Unlucky Charm’: Heineken® and Self-Confessed Jinx Go to Extreme Lengths to Protect the Result at 2025 UEFA Champions League Final

AMSTERDAM, May 30, 2025 (Korea Bizwire) — 45% of football fans* admit they’ve stopped watching a match to avoid jinxing the result. In response, for this year’s UEFA Champions League Final on 31st May in Munich, Heineken® is celebrating this superstition by sending self-confessed jinx Marco Simeone, a lifelong Inter Milan supporter, to a purpose-built bar for [...]

Constellation Brands to Report First Quarter 2026 Financial Results on July 1, 2025 After Market Close and Host Conference Call on July 2, 2025 at 10:30 AM ET

Constellation Brands to Report First Quarter 2026 Financial Results on July 1, 2025 After Market Close and Host Conference Call on July 2, 2025 at 10:30 AM ET

ROCHESTER, N.Y., May 29, 2025 (Korea Bizwire) – Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today it will report financial results for its first quarter ending May 31, 2025, on Tuesday, July 1, 2025, after the close of the U.S. markets by posting the earnings release and financial tables, as well as [...]

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

Teva outlines acceleration path into a leading biopharma company Innovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO® (deutetrabenazine), AJOVY® (fremanezumab), UZEDY® (risperidone) and late-stage pipeline with blockbuster potential Reaffirming 2027 financial targets, including 30% operating profit margin, driven by innovative growth and transformation programs TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (Korea [...]

Unleashing Adventure: VistaJet Reports Rising Demand in Pet Travel and Reveals the Must-Visit Destinations for this Summer

Unleashing Adventure: VistaJet Reports Rising Demand in Pet Travel and Reveals the Must-Visit Destinations for this Summer

Hong Kong / Singapore, May 29, 2025 (Korea Bizwire) – This summer, travelers may fully embrace holiday adventures alongside their beloved pets. VistaJet, the world’s first and only global private aviation company, has witnessed growing demand for pet-friendly summer travel and a 17% increase of flight traffic in 2024. Top destinations for VistaJet flights traveling with [...]

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. (Image from Teva webpage) BD9 is a multibody that targets IL-13 and TSLP, and has potential to treat TH-2-driven inflammatory diseases BD9 designed [...]

Junshi Biosciences Announces Ongericimab’s sNDA Approval in China

Junshi Biosciences Announces Ongericimab’s sNDA Approval in China

SHANGHAI, May 27, 2025 (Korea Bizwire) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (the “NMPA”) has approved two supplemental new drug applications for the ongericimab injection (a recombinant [...]